RxSight (RXST) Payables (2020 - 2026)

RxSight (RXST) has reported Payables for 7 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 89.52% year-over-year to $6.3 million; the trailing twelve-month figure through Jun 2026 stood at $6.3 million (up 89.52% YoY), and the FY2025 full-year result was $5.3 million, up 16.55% from the prior year.
• Payables fell to $6.3 million in Q2 2026 per RXST's latest filing, from $7.1 million in the prior quarter.
• Across five years, Payables topped out at $7.1 million in Q1 2026 and bottomed at $2.6 million in Q1 2022.
• Historically, Payables has averaged $4.5 million across 5 years, with a median of $4.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Payables soared 146.72% in 2022, then slumped 34.29% in 2025.
• Over 5 years, Payables stood at $2.6 million in 2022, then surged by 48.86% to $3.9 million in 2023, then increased by 17.63% to $4.5 million in 2024, then advanced by 16.55% to $5.3 million in 2025, then rose by 19.81% to $6.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $6.3 million, $7.1 million, and $5.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.